The Ministry of Health is analyzing the process of procuring the vaccine in order to define the strategy of immunization against smallpox

The Ministry of Health is analyzing the process of procuring the vaccine in order to define the strategy of immunization against smallpox

With a threat monkey goddesses spreading, the Ministry of Health already evaluates the acquisition process vaccines, to then define an immunization strategy in Brazil. There are no stockpiles of immunizers in the country since the disease was eradicated in the 1970s.

As there is no own vaccine that protects against monkeypox (monkeypox), the World Health Organization (WHO) recommends an immunization agent that works against traditional smallpox (smallpox), as long as it is more modern, second or third generationwhich does not replicate in the human body). This type of medicine proved to be 85% effective against monkeypox, the entity guaranteed.

In some countries, a vaccine that is already highly rated is used. It is called Jynneos (in the United States), Imvamune (in Canada) or Imvanex (in Europe), and is produced by the Danish laboratory Bavarian Nordic. The immunizer was approved in 2019 by the US Food and Drug Administration (FDA), and in 2013 by the European Medicines Agency (EMEA).

In Brazil, however, the product has not yet been registered with the National Agency for Health Surveillance (anvisa).

Any new medicine or vaccine, before being put into use in the country, needs the approval of the National Agency for Health Surveillance (anvisa). Although this is a common procedure, the Agency said that so far there are no requests for vaccines or medicines against monkeypox in Brazil. The initiative must come from pharmaceutical laboratories.

Jynneos is unable to replicate in the human body, is less likely to cause side effects than conventional vaccines, and has been shown to be effective in eliciting a strong immune response. Those who have not been previously vaccinated against smallpox should receive two doses, 28 days apart. But it is still unclear how long the protection will last.

Despite this, the vaccine is not widely available. Faced with the growing cases of monkeypox in the world, Bavarian Nordic announced that it has increased the production of immunizers. The Ministry of Health, however, did not say which vaccine is being analyzed for purchase.

This week, the Secretary of Health Supervision of the Ministry of Health, Arnaldo de Medeiros, reported that the federal government is negotiating the purchase of an immunizer that protects against smallpox, but did not provide more details. This was announced in an interview for the portal metropolis.

According to Medeiros, a meeting was even held with the manufacturing company, and the acquisition was mediated by the Pan American Health Organization (PAHO). As he said, the doses are expected to arrive in the country between the third and fourth quarters of this year.

Who can be vaccinated

The World Health Organization (WHO) does not recommend mass vaccination of the population against monkeypox. According to the entity, only priority groups should receive immunization facilities, such as lab workers exposed to the virus and people who have had close contact with infected people.

Also, according to the WHO, measures to control and diagnose the disease, in addition to vaccinating certain groups, can prevent outbreaks worldwide.

What are the symptoms of monkeypox?

The symptoms are similar, to a lesser extent, to those in elderly patients with smallpox: fever, headache, muscle and back pain for the first five days. Then there are eruptions – on the face, palms and soles -, lesions, pustules and finally scabs.

How is it transmitted?

Infection in early cases occurs through direct contact with blood, body fluids, skin lesions or mucous membranes of infected animals. Secondary transmission from person to person may be the result of close contact with infected airway secretions, lesions on the skin of an infected person, or objects contaminated with recently contaminated biological fluids or materials from the patient’s wounds.

health risk

According to experts, monkeypox should not have the same dimension as covid-19. According to scientist Esther Sabino, a professor at the University of Sao Paulo (USP) and leader of the group responsible for the first sequencing of the virus in Brazil, this virus that causes smallpox in monkeys has no airborne transmission, nor does coronavirus. .

– Monkey goddesses need very close contact in order for people to become infected. Therefore, monkeypox will probably not have the same dimension as Covid, “he said in a statement. interview for the newspaper O Estado de S. Paulo.

confirmed cases in Brazil

Brazil currently has five confirmed cases, three in Sao Paulo, one in Rio Grande do Sulu and one in Rio de Janeiro. Eight cases are still under investigation. An investigation was into one death in Minas Gerais, but it was rejected this Wednesday (15) by the Ezequiel Dias Foundation because of the monkeypox. It is about a 41-year-old man, without a history of travel and contact with a suspected or confirmed case of the disease. The causes of death are still being investigated.

.

Leave a Comment

Your email address will not be published.